Article
Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6.
The Lancet. Oncology - 1 Jul 2015
Yang James C-H, Sequist Lecia V, Geater Sarayut Lucien, Tsai Chun-Ming, Mok Tony Shu Kam, Schuler Martin, Yamamoto Nobuyuki, Yu Chong-Jen, Ou Sai-Hong I, Zhou Caicun, Massey Daniel, Zazulina Victoria, Wu Yi-Long
Abstract excerpt
BACKGROUND: Most patients with non-small-cell lung cancer tumours that have EGFR mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie, common mutations). However, a subset of patients (10%) with mutations in EGFR have tumours that harbour uncommon mutations. There is a paucity of data regarding the sensitivity of these tumours to EGFR inhibitors. Here we present...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.